Advisers say FDA's opioid REMS program needs improvement.
Kate
K
Traynor
D026683:Advisory Committees / Q000592:standards*; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations